Áreas terapeúticas

Current analysis of Invasive Meningococcal Disease (IMD) trends in South Africa, featuring provincial statistics, seasonal patterns, and mortality rates. Highlights significant 53% increase in cases from 2022 to 2023, with special focus on Western Cape's higher incidence rates and nationwide surveillance data from GERMS-SA programme.

Comprehensive overview of risk factors associated with meningococcal carriage and disease transmission, including crowded living conditions, intimate contact, passive smoking, and travel to hyperendemic areas. Essential information for healthcare providers and individuals in high-risk settings such as university dormitories, military barracks, and laboratory environments.

Comprehensive analysis of Invasive Meningococcal Disease (IMD) complications, featuring statistical data from an 868-case Canadian study. Details both neurological and non-neurological complications, including hearing loss, motor deficits, and skin scarring, while exploring the emotional and economic burden on families and caregivers.

Comprehensive guide to Invasive Meningococcal Disease progression, detailing the critical 24-hour timeline from initial flu-like symptoms to life-threatening complications. Essential information for healthcare professionals and concerned individuals about this rapidly progressing infection that requires urgent medical intervention.

Comprehensive overview of Neisseria meningitidis transmission mechanisms, nasopharyngeal carriage, and progression to invasive disease. Features evidence-based information on transmission through respiratory droplets, carriage rates across populations, and the critical role of carriage in disease spread, with special focus on high-risk groups like university students and military personnel.

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Zapraszamy do zapoznania się z materiałem prezentującym SULIQUA® - innowacyjne rozwiązanie w leczeniu cukrzycy typu 2. Dowiedz się, jak można uprościć schemat leczenia, poprawić kontrolę glikemii i zredukować ryzyko hipoglikemii przy jednym wstrzyknięciu dziennie. Materiał zawiera kluczowe informacje o skuteczności terapii i jej wpływie na jakość życia pacjentów.

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies